Protein– tag –
-
UBC Bolsters AI-Driven Drug Discovery and Protein Design with New Research Chairs
UBC Medicine Canada Overview The University of British Columbia's Faculty of Medicine has appointed three world-renowned scientists as Eddie Goldenberg Research Chairs to accelerate breakthroughs in AI-driven protein design, drug deliver... -
BRD4-Targeting PROTAC Nanoassemblies Dramatically Enhance FLASH Radiotherapy, Achieving Robust Tumor Suppression
PMC USA Overview New research reveals that BRD4-targeting PROTAC nanoassemblies (APF) significantly amplify the anti-tumor efficacy of ultra-high dose rate FLASH radiotherapy (FLASH-RT). By efficiently delivering the BRD4 degrader ARV-77... -
AbbVie’s Etentamig: A Next-Generation Bispecific Engager Set to Redefine Multiple Myeloma Treatment
Fierce Biotech USA Overview AbbVie has announced positive Phase 3 clinical trial results for etentamig, a second-generation bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM). Targeting BCMA and CD3, ... -
Democratizing Advanced Immunotherapy: BiTE Therapies Expand into Community Cancer Centers
American Oncology Network USA Overview Bispecific T-cell Engager (BiTE) therapy represents a significant breakthrough in cancer treatment, now experiencing expanding adoption within community oncology facilities across the United States.... -
FDA Grants Fast Track Designation to Four Novel Cancer Therapeutics, Accelerating Development for Urgent Needs
Targeted Oncology USA Overview In August 2026, the U.S. FDA granted Fast Track designation to four novel oncology drugs, significantly accelerating their development and review processes. These include Erasca Inc.'s ERAS-0015 (pancreatic... -
Unlocking TPD’s Promise: Nanomedicine and Programmable Proximity Platforms Revolutionize Degrader Delivery
MDPI Switzerland Overview Nanomedicine and programmable proximity platforms are emerging as pivotal solutions to the delivery challenges inherent in targeted protein degradation (TPD) technologies. Degrader molecules like PROTACs often f... -
Samsung Biologics to Acquire PolyPeptide Group for $1.8B, Expanding CDMO Capabilities into Peptide Therapeutics with $2.2B Capital Raise
Endpoints News South Korea Overview Samsung Biologics announced a capital raise of nearly $2.2 billion to fund its long-term growth strategy, including the acquisition of PolyPeptide Group for $1.8 billion. This acquisition will signific... -
Pin Therapeutics Unveils Oral CK1α Molecular Glue Degrader PIN-5018 for Adenoid Cystic Carcinoma at China TPD Forum, Phase 1 Underway Targeting FDA Accelerated Approval
Korea Biomedical Review South Korea Overview Pin Therapeutics presented PIN-5018, an oral CK1α-selective molecular glue degrader for adenoid cystic carcinoma (ACC), derived from its proprietary PinMARS platform, at the China Targeted Pro... -
Clinical Landscape of Targeted Protein Degradation Explored, Molecular Glues Show Faster Progress with Nanomedicine Delivery Strategies
MDPI Unknown Overview A new review analyzes the clinical landscape of targeted protein degradation (TPD), focusing on PROTACs and molecular glue degraders, noting that the smaller molecular size of molecular glues may enable faster clini... -
CDMO Curia Massively Expands Sterile Fill-Finish Capacity in UK, US for Biologics and ADCs
Packaging Digest UK, USA Overview CDMO Curia has significantly expanded its sterile fill-finish manufacturing facilities in Glasgow, UK, and Albuquerque, US, to meet surging demand for biologics and highly potent antibody-drug conjugates...
